Research programme: cancer therapeutics - Le Sun PharmaceuticalsAlternative Names: LS-007 - Le Sun Pharmaceuticals; LS-008; LS-078; LSF-202; LSF-206
Latest Information Update: 19 Aug 2014
At a glance
- Originator Le Sun Pharmaceuticals
- Developer Le Sun Pharmaceuticals; Yabao Pharmaceutical Group
- Class Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Cyclin dependent kinase 9 inhibitors; Maturation-promoting factor inhibitors; Polo-like kinase 1 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 01 Jan 2014 Preclinical trials in Cancer in China (PO)